Recipharm Expands Israel Capacity
Swedish CDMO Recipharm is investing in a capacity expansion at its facility located south of Tel Aviv in Israel, in order to support growing demand for cGMP clinical supply of APIs and intermediates.
At the facility located in the Weizmann Science Park, Recipharm will add a full GMP chemical unit that will include a number of new R&D laboratories and technologies. The expansion is expected to be fully operational by the end of 2021.
The CDMO said the new capabilities will enable it to support customers through their development projects, from early medicinal chemistry into commercialization through a single integrated flow.
The team in Israel specializes in medicinal chemistry, offering various services in chemical synthesis and analysis, including said Recipharm, some very demanding and novel specialties.
Late last month, Recipharm announced that it had signed a letter of intent with Moderna to formulate, fill and finish the US biotech’s mRNA-1273 Covid-19 vaccine candidate at its facility in Monts, France. The Stockholm-based company has already reserved capacity to support anticipated demand for the vaccine and is recruiting extra staff and making certain investments to enable technology transfer and scale-up to commence imminently.
Author: Elaine Burridge, Freelance Journalist
